Frontiers in pharmacology

Risk of tumors with semaglutide treatment in people with type 2 diabetes: a review and combined analysis of clinical trials

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗OA ↗

Updated

Abstract

Semaglutide is prescribed to improve glycemic control in adults with type 2 diabetes.

  • The use of semaglutide may influence tumor development, raising concerns regarding its safety.
  • Current discussions focus on the relationship between semaglutide and tumorigenesis.
  • Further research is needed to clarify the potential risks associated with semaglutide in this context.

Simplified

Full Text

Full text is available at the source.
View Full Text ↗

Related papers

Nov '22
Folic acid supplements and malaria risk and severity in people using antifolate malaria drugs in affected areas
cited by 30 papers
systematic review
Jul '26
Risk of worsening diabetic eye disease linked to GLP-1 receptor agonist treatments
top 30% journal
Dec '25
Semaglutide given under the skin or by mouth and heart health in people with type 2 diabetes: a combined analysis of clinical trials
top 20% journal
systematic review
Feb '26
Link Between GLP-1 Drugs and Colon Cancer Risk in Adults with Type 2 Diabetes or Obesity
top 10% journal
cited by 2 papers
systematic review
Feb '25
Comparing how incretin drugs affect blood sugar, weight, and blood pressure in overweight adults with or without type 2 diabetes
top 10% journal
cited by 16 papers
systematic review
Sep '25
Semaglutide’s effects on irregular heartbeats, major heart problems, and small blood vessel issues in type 2 diabetes patients
top 10% journal
cited by 5 papers
systematic review

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free

Recent issues from the glp-1 therapies brief

issue #54
GLP-1 drugs don't build habits — and that gap is costing patients their results
5 days ago7 studies
issue #53
Semaglutide slowed aging and extended lifespan in older female mice
1 week ago7 studies
issue #52
GLP-1 drugs linked to lower Parkinson's risk in people with type 2 diabetes
2 weeks ago7 studies
issue #51
Semaglutide linked to nearly double the risk of a rare eye condition in people with diabetes
3 weeks ago7 studies
issue #50
A once-daily pill beat placebo on weight loss — and it wasn't semaglutide
4 weeks ago7 studies
issue #49
GLP-1 drugs work even without weight loss — and scientists are finally mapping why
5 weeks ago7 studies
issue #48
Stop the drug, regain the weight: pooled data puts the average rebound at 7%
6 weeks ago7 studies
issue #47
The brain region that explains why blocking and activating the same receptor both cause weight loss
7 weeks ago7 studies
issue #46
GLP-1 drugs linked to lower depression and bipolar disorder risk in large genetic study
8 weeks ago7 studies
issue #45
Stopping GLP-1 drugs linked to higher depression and anxiety risk in type 2 diabetes patients
9 weeks ago7 studies
explore the archive
See more issues from the glp-1 therapies brief